Advanced Breast Cancer Webcast 2021 - attendee accreditation & evaluation Survey

Question Title

* 1. NACCME designates the full on-demand activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). If you would like to receive a certificate for your participation in the full on-demand webcast, please add your name and email address here and complete the evaluation survey. You will then be sent your certificate shortly:

Name

Email Address (to send certificate to)

Question Title

* 2. How would you rate the overall quality of the webcast? (1= Poor, 10= Excellent)

Clear

i We adjusted the number you entered based on the slider’s scale.

Question Title

* 3. What did you like best about the webcast?

Question Title

* 4. How useful was the webcast for your practice?

Extremely useful

Useful

Fairly useful

Not useful

If this activity was not useful, please say why.

Question Title

* 5. How well did the webcast fulfil the following learning objectives?

After participating in the webcast I am now able to…

	Very well	Well	Not well	Not at all
Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer	Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer Very well	Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer Well	Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer Not well	Summarize the latest data and guidelines on the optimal use of CDK4/6 inhibitors in the treatment of HR+ HER2- advanced breast cancer Not at all
Compare the toxicity profiles of the different CDK 4/6 inhibitors in order to make optimal treatment decisions	Compare the toxicity profiles of the different CDK 4/6 inhibitors in order to make optimal treatment decisions Very well	Compare the toxicity profiles of the different CDK 4/6 inhibitors in order to make optimal treatment decisions Well	Compare the toxicity profiles of the different CDK 4/6 inhibitors in order to make optimal treatment decisions Not well	Compare the toxicity profiles of the different CDK 4/6 inhibitors in order to make optimal treatment decisions Not at all
Apply evidence-based, personalised best practice in the selection, sequencing, and dosing of CDK 4/6 inhibitors	Apply evidence-based, personalised best practice in the selection, sequencing, and dosing of CDK 4/6 inhibitors Very well	Apply evidence-based, personalised best practice in the selection, sequencing, and dosing of CDK 4/6 inhibitors Well	Apply evidence-based, personalised best practice in the selection, sequencing, and dosing of CDK 4/6 inhibitors Not well	Apply evidence-based, personalised best practice in the selection, sequencing, and dosing of CDK 4/6 inhibitors Not at all

Question Title

* 6. Was the presented information well balanced and consistently supported by a valid scientific evidence base?

Very much

Somewhat

Not much

Not at all

Question Title

* 7. How useful were the individual sessions for you?

	Extremely useful	Useful	Fairly useful	Not useful
CDK4/6 inhibitors in HR+ HER2- ABC Treatment – Guidelines and Evidence	CDK4/6 inhibitors in HR+ HER2- ABC Treatment – Guidelines and Evidence Extremely useful	CDK4/6 inhibitors in HR+ HER2- ABC Treatment – Guidelines and Evidence Useful	CDK4/6 inhibitors in HR+ HER2- ABC Treatment – Guidelines and Evidence Fairly useful	CDK4/6 inhibitors in HR+ HER2- ABC Treatment – Guidelines and Evidence Not useful
Patient selection and sequencing of CDK4/6 inhibitors	Patient selection and sequencing of CDK4/6 inhibitors Extremely useful	Patient selection and sequencing of CDK4/6 inhibitors Useful	Patient selection and sequencing of CDK4/6 inhibitors Fairly useful	Patient selection and sequencing of CDK4/6 inhibitors Not useful
Monitoring and managing treatment-related toxicities	Monitoring and managing treatment-related toxicities Extremely useful	Monitoring and managing treatment-related toxicities Useful	Monitoring and managing treatment-related toxicities Fairly useful	Monitoring and managing treatment-related toxicities Not useful

Question Title

* 8. As a result of viewing this webcast, will you make any measurable changes in your role?

Yes

Possibly, after additional training/information

No, but the content affirms my current practice

No, I am unable to implement this information

If YES, can you provide an example of how this event will influence your future practice?

If NO, what are the barriers that prevent you from making changes?

Question Title

* 9. Do you agree that the presented information was overall free of commercial and other bias?

Strongly agree

Agree

Rather disagree

Strongly disagree

Advanced Breast Cancer Webcast 2021 - attendee accreditation & evaluation

WEBCAST: Optimizing CDK4/6 inhibition in HR+ HER2- advanced breast cancer

Question Title

Question Title

* 2. How would you rate the overall quality of the webcast? (1= Poor, 10= Excellent)

Question Title

* 3. What did you like best about the webcast?

Question Title

* 4. How useful was the webcast for your practice?

Question Title

* 5. How well did the webcast fulfil the following learning objectives?

After participating in the webcast I am now able to…

Question Title

* 6. Was the presented information well balanced and consistently supported by a valid scientific evidence base?

Question Title

* 7. How useful were the individual sessions for you?

Question Title

* 8. As a result of viewing this webcast, will you make any measurable changes in your role?

Question Title

* 9. Do you agree that the presented information was overall free of commercial and other bias?

Question Title

* 10. Do you have any final questions or comments?

Question Title

Question Title

* 2. How would you rate the overall quality of the webcast? (1= Poor, 10= Excellent)

Question Title

* 3. What did you like best about the webcast?

Question Title

* 4. How useful was the webcast for your practice?

Question Title

* 5. How well did the webcast fulfil the following learning objectives?After participating in the webcast I am now able to…

Question Title

* 6. Was the presented information well balanced and consistently supported by a valid scientific evidence base?

Question Title

* 7. How useful were the individual sessions for you?

Question Title

* 8. As a result of viewing this webcast, will you make any measurable changes in your role?

Question Title

* 9. Do you agree that the presented information was overall free of commercial and other bias?

Question Title

* 10. Do you have any final questions or comments?

* 5. How well did the webcast fulfil the following learning objectives?

After participating in the webcast I am now able to…